[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603130":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":22,"centralContacts":28,"locations":38,"responsibleParty":56,"collaborators":22,"id":58,"slug":22,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":22,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":22,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":22,"overallStatus":41,"whyStopped":22,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mansoura University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Anticoagulant in cirrhosis with HCC","EXPERIMENTAL","HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)",[13],"Drug: Enoxaparin, warfarrin, or apixaban",{"label":15,"type":10,"description":16,"interventionNames":17},"Anticoagulant in Cirrhosis without HCC","Benign thrombus in cirrhotic patient on anticoagulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"No anticoagualnt in Cirrhosis with or without HCC","NO_INTERVENTION","cirrhotic patients with thrombosis with or without HCC not on anticoagulant",null,[24],{"type":25,"name":26,"description":26,"armGroupLabels":27,"otherNames":22},"DRUG","Enoxaparin, warfarrin, or apixaban",[15,9],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":22,"email":33},"Dalia Elsayed Ganady, MBBS","CONTACT","+201095529264","dalia.tawfik97@gmail.com",{"name":35,"role":31,"phone":36,"phoneExt":22,"email":37},"Hatem Elalfy, PhD","+201224790518","elalfy2004@mans.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Mansoura University Hospitals","RECRUITING","Al Mansurah","Dakahlia Governorate","35511","Egypt",{"type":47,"coordinates":48},"Point",[49,50],31.38069,31.03637,{"lat":50,"lon":49},[53],{"name":54,"role":31,"phone":55,"phoneExt":22,"email":33},"Dalia E Tawfik","+20 1095529264",{"type":57,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100603130",false,"NCT07132515","Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC","Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \\& B\n\nExclusion Criteria:\n\n* Platelets\\\u003C10000, Createnine \\>1.9, Budd ciarri, Uncontrolled active bleeding","ALL","18 Years","70 Years",{"count":68,"type":69},100,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","We will give an anticoagulant against portal vein thrombosis, and watch for the results.",[75,76,77],"Cirrhosis","HCC - Hepatocellular Carcinoma","Portal Vein Thrombosis","2025-08-17",{"date":80,"type":81},"2025-08-20","ACTUAL",{"date":83,"type":81},"2023-08-15",{"date":85,"type":69},"2025-08",{"name":5,"class":6},1]